Trial · NCT01853046
Results by group138
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 138
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib | 67.2 | Geometric Coefficient of Variation 45.5 | mg*h/L |
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib | 76.6 | Geometric Coefficient of Variation 50.3 | mg*h/L |
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-2 | 27.8 | Geometric Coefficient of Variation 80.4 | mg*h/L |
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-2 | 19.0 | Geometric Coefficient of Variation 58.7 | mg*h/L |
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-5 | 5.25 | Geometric Coefficient of Variation 145 | mg*h/L |
AUC(0-tlast) [Area Under the Concentration-time Curve After Single (First) Dose From Time Zero to the Last Data Point >LLOQ (Lower Limit of Quantification)] for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-5 | 2.34 | Geometric Coefficient of Variation 79.8 | mg*h/L |
| AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-7 | 3.607 | Standard Deviation 1.124 | percentage of dose |
| AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-7 | 1.309 | Standard Deviation 0.649 | percentage of dose |
| AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-8 | 1.120 | Standard Deviation 0.737 | percentage of dose |
| AE,ur(0-24) (Amount of Drug Excreted Via Urine During the Collection Interval 0-24 Hours Post Administration) for Metabolites M-7 and M-8 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-8 | 0.184 | Standard Deviation 0.229 | percentage of dose |
| AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib (n=6, 3) | 59.5 | Geometric Coefficient of Variation 26.1 | mg*h/L |
| AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib (n=6, 3) | 98.7 | Geometric Coefficient of Variation 71.0 | mg*h/L |
| AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-2 (n=13, 4) | 32.6 | Geometric Coefficient of Variation 89.0 | mg*h/L |
| AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-2 (n=13, 4) | 20.8 | Geometric Coefficient of Variation 65.4 | mg*h/L |
| AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-5 (n=0, 0) | NA | Geometric Coefficient of Variation NA | mg*h/L |
| AUC (Area Under the Plasma Concentration vs. Time Curve From Zero to Infinity After Single (First) Dose) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-5 (n=0, 0) | NA | Geometric Coefficient of Variation NA | mg*h/L |
| AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib | 30.0 | Geometric Coefficient of Variation 39.8 | mg*h/L |
| AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib | 28.4 | Geometric Coefficient of Variation 62.0 | mg*h/L |
| AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment | Regorafenib metabolites M-2 | 13.5 | Geometric Coefficient of Variation 70.0 | mg*h/L |
| AUC(0-24) (AUC From Time Zero to 24 Hours p.a. After Single (First) Dose Administration) for Regorafenib and Its Pharmacologically Active Metabolites M-2 and M-5 | Regorafenib(Stivarga,BAY73-4506)-Severe Renal Impairment | Regorafenib metabolites M-2 | 7.93 | Geometric Coefficient of Variation 72.7 | mg*h/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01853046/results